British consultant, speaker and author, Richard Barker – a key opinion leader on UK healthcare – gives his take on the recently launched ‘Life Sciences Industrial Strategy’, the importance of facilitating accelerated access to medicines, and the potential fallout from Brexit to the UK’s life sciences ecosystem.
On the positive side, UK-based biotech companies are raising considerable venture capital and two or three international companies have recently announced they are making new investments in the UK
